

# WIKINGO Project Systematic Analysis

## Tables & Figures.

Proyecto Vikingo

September 29, 2016

`proyectovikingo@proyectovikingo.es`

## Contents

### List of Tables

1	Participant characteristics . . . . .	3
2	According to Local Recurrence . . . . .	4
3	According to Metastasis . . . . .	6
4	According to Exitus . . . . .	8
5	Incidence by outcome [95% CI] . . . . .	13

### List of Figures

1	Local Recurrence . . . . .	5
2	Metastasis . . . . .	7
3	Exitus . . . . .	9
4	Local Recurrence, according to Type of Resection: . . . . .	10
5	Metastasis, according to Type of Resection: . . . . .	11
6	Survival, according to Type of Resection: . . . . .	12

Table 1: Participant characteristics

	[ALL] N=308	N
Age	70.3 (11.7)	308
Sex: Men	204 (66.2%)	308
Tumor level:		308
0-6cm	139 (45.1%)	
7-12cm	155 (50.3%)	
13-15cm	14 (4.55%)	
Tumor stage:		308
0	37 (12.0%)	
I	103 (33.4%)	
II	69 (22.4%)	
III	99 (32.1%)	
Neoadjuvant treatment	204 (66.2%)	308
Type of resection:		308
Abdominoperineal resection	94 (30.5%)	
Anterior resection	176 (57.1%)	
Hartmann	38 (12.3%)	
Perforation	19 (6.17%)	308
Invasion circumferential margin	25 (8.12%)	308
Mesorecto quality:		306
Satisfactory	244 (79.7%)	
Partial	50 (16.3%)	
No-satisfactory	12 (3.92%)	
Recidive	9 (2.92%)	308
Months to recidive	15.0 [1.00;37.0]	308
Metastasis	25 (8.12%)	308
Months to Metastasis	15.0 [1.00;35.0]	308
Exitus	48 (15.6%)	308
Months to exitus	15.0 [1.00;37.0]	308


Table 2: According to Local Recurrence

	No event n= 299	Event n= 9	Crude HR	p-value	Multivariate HR	p-value
Age (10y)	7.03 (1.16)	7.09 (1.45)	1.14 [0.63;2.09]	0.663	1.18 [0.66; 2.08]	0.578
Sex: Men	197 (65.9%)	7 (77.8%)	1.76 [0.36;8.50]	0.483	3.23 [0.39; 26.56]	0.274
Tumor level:						
0-6cm	134 (44.8%)	5 (55.6%)	77487079 [0.00;.]	0.999	339835270.24 [0.00; Inf]	0.999
7-12cm	151 (50.5%)	4 (44.4%)	70009350 [0.00;.]	0.999	381559363.38 [0.00; Inf]	0.999
Tumor stage:						
0	37 (12.4%)	0 (0.00%)	0.00 [0.00;.]	0.998	0.00 [0.00; Inf]	0.999
II	66 (22.1%)	3 (33.3%)	4.79 [0.50;46.2]	0.176	1.42 [0.10; 20.47]	0.795
III	94 (31.4%)	5 (55.6%)	7.41 [0.86;63.8]	0.068	2.09 [0.19; 23.24]	0.549
Neoadjuvant treatment	198 (66.2%)	6 (66.7%)	0.88 [0.22;3.53]	0.858	0.67 [0.12; 3.77]	0.65
Type of resection:						
Abdominoperineal resection	89 (29.8%)	5 (55.6%)	2.03 [0.54;7.64]	0.294	1.33 [0.04; 40.80]	0.87
Hartmann	38 (12.7%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0.00; Inf]	1
Perforation	16 (5.35%)	3 (33.3%)	7.30 [1.81;29.4]	0.005	12.40 [1.51;102.10]	0.019
Invasion circumferential margin	21 (7.02%)	4 (44.4%)	9.47 [2.52;35.6]	0.001	8.43 [1.69; 41.96]	0.009
Mesorrecto quality:						
Partial	48 (16.2%)	2 (22.2%)	1.36 [0.28;6.55]	0.704	0.40 [0.04; 3.83]	0.425
No-satisfactory	12 (4.04%)	0 (0.00%)	0.00 [0.00;.]	0.999	0.00 [0.00; Inf]	0.999

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorrecto Quality, Satisfactory

Figure 1: Local Recurrence



Months	0	12	24	36	48	60
N:	308	169	117	79	48	32


Table 3: According to Metastasis

	No event n= 283	Event n= 25	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	7.03 (1.16)	6.94 (1.23)	0.99 [0.71;1.39]	0.973	0.97 [0.69; 1.39]	0.888	308
Sex: Men	188 (66.4%)	16 (64.0%)	0.97 [0.43;2.20]	0.943	1.10 [0.45; 2.68]	0.836	308
Tumor level:							308
0-6cm	130 (45.9%)	9 (36.0%)	0.60 [0.13;2.77]	0.512	2.90 [0.38;22.12]	0.304	
7-12cm	141 (49.8%)	14 (56.0%)	0.89 [0.20;3.93]	0.879	1.17 [0.23; 5.98]	0.848	
Tumor stage:							308
0	36 (12.7%)	1 (4.00%)	2.63 [0.24;29.0]	0.431	2.78 [0.24;32.11]	0.413	
II	62 (21.9%)	7 (28.0%)	5.21 [1.08;25.1]	0.040	6.22 [1.24;31.30]	0.027	
III	84 (29.7%)	15 (60.0%)	9.98 [2.28;43.7]	0.002	10.58 [2.30;48.62]	0.002	
Neoadjuvant treatment	189 (66.8%)	15 (60.0%)	0.67 [0.30;1.50]	0.331	0.65 [0.26; 1.64]	0.364	308
Type of resection:							308
Abdominoperineal resection	89 (31.4%)	5 (20.0%)	0.48 [0.18;1.29]	0.146	0.21 [0.04; 0.97]	0.045	
Hartmann	37 (13.1%)	1 (4.00%)	0.94 [0.12;7.16]	0.956	0.93 [0.10; 8.46]	0.948	
Perforation	17 (6.01%)	2 (8.00%)	1.34 [0.32;5.70]	0.692	1.59 [0.32; 8.02]	0.572	308
Invasion circumferential margin	20 (7.07%)	5 (20.0%)	2.76 [1.03;7.36]	0.043	1.93 [0.66; 5.66]	0.23	308
Mesorecto quality:							306
Partial	46 (16.4%)	4 (16.0%)	0.91 [0.31;2.67]	0.868	1.01 [0.32; 3.20]	0.981	
No-satisfactory	11 (3.91%)	1 (4.00%)	1.08 [0.14;8.08]	0.940	1.13 [0.14; 9.20]	0.909	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory

Figure 2: Metastasis



Months	0	12	24	36	48	60
N:	308	166	109	73	45	31

Table 4: According to Exitus


	No event n= 260	Event n= 48	Crude HR	p-value	Multivariate HR	p-value	N
Age (10y)	6.94 (1.15)	7.49 (1.13)	1.68 [1.24;2.28]	0.001	1.53 [1.12; 2.09]	0.008	308
Sex: Men	174 (66.9%)	30 (62.5%)	0.84 [0.47;1.52]	0.571	0.82 [0.43; 1.56]	0.543	308
Tumor level:							308
0-6cm	114 (43.8%)	25 (52.1%)	3.47 [0.47;25.6]	0.222	6.71 [0.72;62.27]	0.094	
7-12cm	133 (51.2%)	22 (45.8%)	3.13 [0.42;23.3]	0.265	3.41 [0.43;27.10]	0.245	
Tumor stage:							308
0	35 (13.5%)	2 (4.17%)	0.80 [0.18;3.57]	0.767	0.88 [0.19; 4.17]	0.873	
II	60 (23.1%)	9 (18.8%)	1.10 [0.46;2.62]	0.825	1.66 [0.65; 4.22]	0.285	
III	74 (28.5%)	25 (52.1%)	2.71 [1.36;5.41]	0.005	3.11 [1.46; 6.64]	0.003	
Neoadjuvant treatment	176 (67.7%)	28 (58.3%)	0.61 [0.35;1.09]	0.095	0.70 [0.36; 1.38]	0.306	308
Type of resection:							308
Abdominoperineal resection	79 (30.4%)	15 (31.2%)	1.01 [0.53;1.91]	0.977	0.52 [0.19; 1.44]	0.21	
Hartmann	31 (11.9%)	7 (14.6%)	4.35 [1.85;10.2]	0.001	2.43 [0.75; 7.92]	0.14	
Perforation	16 (6.15%)	3 (6.25%)	1.03 [0.32;3.34]	0.955	1.58 [0.44; 5.69]	0.483	308
Invasion circumferential margin	17 (6.54%)	8 (16.7%)	2.35 [1.10;5.03]	0.028	1.82 [0.80; 4.17]	0.155	308
Mesorecto quality:							306
Partial	44 (17.0%)	6 (12.8%)	0.72 [0.30;1.69]	0.448	0.63 [0.24; 1.63]	0.338	
No-satisfactory	11 (4.25%)	1 (2.13%)	0.63 [0.09;4.60]	0.648	0.71 [0.09; 5.30]	0.736	

Reference categories:

- Age, a decade
- Sex, Women
- Tumor level, 13-15cm
- Tumor stage: 1
- Neoadjuvant treatment, No
- Type of resection, Anterior resection
- Perforation, No
- Invasion circumferential margin, No
- Mesorecto Quality, Satisfactory




Figure 3: Exitus




Months	0	12	24	36	48	60
N:	308	169	118	80	49	33

Figure 4: Local Recurrence, according to Type of Resection:




Tiempo	0	12	24	36	48	60
Abd	94	58	38	29	23	15
Ant	176	108	77	49	25	17
H	38	10	3	2	1	0

Figure 5: Metastasis, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	94	58	36	27	21	16
Ant	176	107	72	46	23	15
H	38	9	2	1	1	0

Figure 6: Survival, according to Type of Resection:



Tiempo	0	12	24	36	48	60
Abd	94	59	38	28	23	16
Ant	176	108	78	51	26	17
H	38	10	3	2	1	0

Table 5: Incidence by outcome [95% CI]

Months	Local Recurrence	Metastasis	Exitus
12	0.54 [1.6; 0]	2.99 [5.34; 0.59]	6.51 [9.8; 3.1]
24	2.69 [5.28; 0.02]	10.79 [15.61; 5.7]	13.76 [18.76; 8.44]
36	3.68 [6.87; 0.38]	14.71 [20.55; 8.44]	21.35 [27.77; 14.37]
48	6.79 [11.96; 1.32]	18.93 [26.03; 11.14]	30.54 [38.5; 21.54]
60	10.81 [17.96; 3.04]	21.18 [29.18; 12.28]	39.99 [49.36; 28.9]